"fibrosis quística" in English

Date of the most recent search of the Cystic Fibrosis Trials Register: 14 March 2011.

Cystic fibrosis (CF) is a genetic disorder with multiorgan effects.

Antifungal therapy for ABPA in cystic fibrosis needs to be evaluated.

Cystic fibrosis is a genetic disorder which can lead to multiorgan dysfunction.

Staphylococcus aureus causes pulmonary infection in young children with cystic fibrosis (CF).

Cystic fibrosis is a genetic disorder which mainly affects the lungs.

Nasal polyps frequently occur in people with cystic fibrosis.

Cystic fibrosis is a genetic, life-threatening disorder affecting multiple organs.

aeruginosa) lung infection is of great importance in managing cystic fibrosis lung disease.

To evaluate the effectiveness of inhaled bronchodilators in people with CF.

Antioxidant micronutrients may be a worthwhile addition to current treatment in cystic fibrosis.

People with cystic fibrosis have a higher risk of chronic lung disease.

Reduction of lung inflammation is one of the goals of cystic fibrosis (CF) therapy.

Impaired mucociliary clearance characterises lung disease in cystic fibrosis (CF).

Cystic fibrosis causes frequent lung infection and the airways become blocked with mucus.

There were few trials included in the review whose quality was not well reported.

Cystic fibrosis is a serious genetic disorder that affects many organs (e.g.

There are several thiol derivatives, and it is unclear which of these may be beneficial in cystic fibrosis.

Have your say!'Your views on The Cochrane Library: survey'

Randomised trials of mucolytic treatment in people with bronchiectasis but not cystic fibrosis.